Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martina Zappa has a total of 215 co-authors. Here are the top co-authors by number of shared publications:

  • Fabio Angeli

    Department of Medicine and Technological Innovation (DiMIT), University of Insubria, Varese, Italy; Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Italy

    21 shared publications
  • Paolo Verdecchia

    Associazione Umbra Cuore e Ipertensione and Division of Cardiology, Hospital S. Maria della Misericordia, Perugia, Italy

    20 shared publications
  • Antonio Spanevello

    Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

    14 shared publications
  • Dina Visca

    Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

    8 shared publications
  • Dina Visca

    Department of Medicine and Surgery, University of Insubria - Varese-Como, Division of Pulmonary Rehabilitation, Istituti Clinici Maugeri, IRCCS, Tradate, Italy

    6 shared publications
  • Gianpaolo Reboldi

    University of Perugia

    5 shared publications

Latest Publications

  • Open Access

    The remission paradox: population stability masking individual instability in biologic-treated severe asthma

    by Francesco Ardesi, Marco Vanetti, Federico Fassio, Rosella Centis, Martina Zappa, Patrizia Pignatti, Veronica Capuano, Giovanni Battista Migliori, Antonio Spanevello, Dina Visca

    Extract The management of severe asthma has been redefined by targeted biologic therapies [1], changing not only patient outcomes but also the way treatment success is conceptualized and measured [2]. Traditional frameworks categorized clinical benefit from non-response to response, mainly based on exacerbation reduction and oral corticosteroid (OCS) sparing [3, 4]. Recently, remission has emerged as a more ambitious treatment goal, integrating absence of exacerbations and OCS use with adequate symptom control and preserved or stable lung function [5, 6].

  • Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma

    by Nicola Scichilone, Giulia Genduso, Diego Bagnasco, Alessandro Barone, Salvatore Battaglia, Alida Benfante, Benedetta Bondi, Matteo Bonini, Luisa Brussino, Giovanna Elisiana Carpagnano, et al.

  • Neutrophil-to-lymphocyte ratio: A disease severity biomarker in stable chronic obstructive pulmonary disease?

    by Marco Vanetti, Dina Visca, Francesco Ardesi, Martina Zappa, Sara Pessano, Patrizia Pignatti, Leonardo M Fabbri, Antonio Spanevello


  • Open Access

    Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe

    by Dace Matīsa, Aruna T. Bansal, Saša Rink, Anna Freeman, Betty Frankemölle, Mehar Singh, Jacob K. Sont, Apostolos Bossios, Ben Ainsworth, Michael Hyland, et al.

    Background: Multimorbidity refers to the presence of multiple co-existing conditions, but is often underappreciated in the context of severe asthma (SA) management. We sought to identify differences in approaches to multimorbidity management in SA, variability in access to multidisciplinary team (MDT) resources, and whether physician perspectives on multimorbidity differ between SA specialists and general respiratory physicians. Methods: The Severe Heterogeneous Asthma Registry, Patient-centred (SHARP) Clinical Research Collaboration circulated an online physician survey via European national respiratory societies to assess a) available resources to address multimorbidity and b) physician perspectives on multimorbidity in SA. Results: 495 responses from 25 European countries included 48% SA specialists and 52% general respiratory physicians. SA specialists had more experience with SA patients (20% seeing>60 patients/month) compared to general respiratory physicians. SA specialists had greater access to multidisciplinary care – including better access to MDT, allied health professionals and referrals to external specialists and therefore more routinely assessed comorbidities and considered them greater influences on their practice. They also considered multimorbidity to a greater degree, and rated its impact on their patients’ asthma outcomes (and general health outcomes) as more substantial. Conclusions: Alongside more experience of treating SA, SA specialists have increased awareness of multimorbidity and better resources to manage it. However, access to MDTs remains a significant gap for both SA specialists and general respiratory physicians. Furthermore, both groups identified a high need for further education and training about multimorbidity. These findings highlight key areas for improvement in clinical practice, resources and training.

  • Open Access

    Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries

    by Anna Freeman, Saša Rink, Aruna T. Bansal, Betty Frankemölle, Mehar Singh, Jacob K. Sont, Apostolos Bossios, Ben Ainsworth, Michael Hyland, Rekha Chaudhuri, et al.


  • Open Access

    Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis

    by Mauro Maniscalco, Pasquale Ambrosino, Claudio Candia, Antonino Di Stefano, Isabella Gnemmi, Martina Zappa, Nicolino Ambrosino, Dina Visca, Andrea Motta

    Background: Mepolizumab improves asthma control in severe eosinophilic asthma (SEA). However, its multidimensional effects on airway and systemic biomarkers are still incompletely understood. Methods: In this prospective study, 15 SEA patients were evaluated at baseline (T0), 6 (T6), and 12 months (T12) after starting mepolizumab. Lung function, FeNO values, asthma control, blood eosinophil count (BEC), cytokines, and metabolomic profiles (1H-NMR) were evaluated in serum, nasal secretions, and exhaled breath condensate (EBC). Univariate and multivariate (PCA, OPLS-DA) analyses were performed. Results: Mepolizumab reduced exacerbations, from a median of 2 at T0 to 0 at both T6 (p = 0.001) and T12 (p = 0.003). ACT improved from 18.7 ± 4.7 at baseline to 23.0 ± 2.8 at T6 (p = 0.026) and 23.4 ± 3.3 at T12 (p = 0.032), while FEV1 increased by 270 mL at T6 (p = 0.032) and remained stable at T12. Median BEC decreased from 450.0 (350.0–560.0) to 65.0 (50.0–87.5) cells/μL at T6 and to 50.0 (35.0–160.0) at T12 (p < 0.001), while FeNO showed a non-significant downward trend. IL-13 significantly decreased in serum and nasal secretions at T6 and T12, while IL-5 increased in nasal secretions at both timepoints and remained unchanged in serum. IL-2 showed opposite trends in serum and nasal samples, whereas GM-CSF and IFN-γ increased in nasal secretions at T12. Metabolomic profiling suggested compartment-specific changes, with decreased short-chain alcohols in EBC, increased amino acids in nasal secretions and serum at T6, and elevated pyruvate in serum at T12, although none reached statistical significance in univariate analysis. Conclusions: Mepolizumab induced consistent clinical, immunologic, and metabolic changes across compartments, supporting the use of integrated cytokine and 1H-NMR metabolomic profiling as a complementary approach for response assessment in SEA.


  • Open Access

    ERS Congress 2024: highlights from the Airway Diseases Assembly

    by Clarice X. Lim, Reshed Abohalaka, Ran Wang, Dominic L. Sykes, Francesco Ardesi, Martina Zappa, Matteo Bonini, Gert-Jan Braunstahl, Alexander G. Mathioudakis, Robert J. Snelgrove, et al.

    This article presents highlights from #ERSCongress 2024 from Assembly 5 (airway diseases, asthma, COPD and chronic cough) https://bit.ly/4070nNw.


  • Open Access

    Exploring the neutrophilic pattern in asthma: are “intermediate” and “high” neutrophilic patients the same population?

    by Dina Visca, Francesco Ardesi, Martina Zappa, Patrizia Pignatti, Rosella Centis, Giovanni Battista Migliori, Federico Fassio, Paola Baiardi, Marco Vanetti, Fabio Luigi Massimo Ricciardolo, et al.

    Extract Asthma is a heterogeneous disease, generally characterised by chronic inflammation of the airways. Phenotyping has recently become a core tool to optimise its management and treatment [1] and biomarkers identification is now even more crucial. Blood eosinophils count is the most widely available inflammatory biomarker used for both therapeutic guidance and monitoring treatment response. Induced sputum (IS) is the gold-standard for a non-invasive assessment of airway inflammatory cell distribution. Four patterns have been identified based on the percentage of eosinophils and neutrophils in IS: eosinophilic, neutrophilic, mixed granulocytic and pauci-granulocytic [2].


  • Open Access

    Eosinophils in chronic obstructive pulmonary disease

    by Marco Vanetti, Dina Visca, Francesco Ardesi, Martina Zappa, Patrizia Pignatti, Antonio Spanevello

    Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterised by chronic respiratory symptoms, fixed airway obstruction and persistent inflammation that leads to a progressive airflow limitation. Although COPD has traditionally been linked to neutrophilic inflammation, recent studies have identified a subset of patients – approximately 20%–40% – with elevated eosinophil levels in blood and sputum. Emerging evidence suggests that eosinophilic inflammation has a pivotal role in a subset of COPD patients and may influence disease progression, exacerbation frequency and therapeutic responses. This narrative review provides a comprehensive analysis of the role of eosinophils in COPD with particular attention to their role as biomarkers in blood and sputum. We evaluate the prevalence of eosinophilic inflammation in COPD exanimating different thresholds used in blood and in sputum to define it. In addition, we focus on eosinophilic COPD phenotype as a treatable trait, emphasising recent evidence that supports the effectiveness of biological target therapy.


  • Heterozygous Alpha-1 Antitrypsin Deficiency in COPD patients

    by Martina Zappa, Marco Vanetti, Patrizia Pignatti, Sarah Grossi, Francesci Ardesi, Rosella Centis, Dina Visca, Antonio Spanevello

    Background Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant condition characterised by a protease/antiprotease imbalance due to a decreased AAT concentration and activity in both serum and tissue. Few studies have investigated whether heterozygous genotype of the SERPINA1 gene, may influence symptoms and disease control in chronic obstructive pulmonary disease patients (COPD). Aim To assess whether the presence of a heterozygous genotype of SERPINA1 in patients with COPD may be associated with disease control, systemic inflammation, lung function and comorbidities prevalence compared to COPD patient with a homozygous phenotype (MM). Methods COPD patients belonging to GOLD grades 2-3-4 were analysed. The analysed variables were comorbidities, smoking habits, blood eosinophils and neutrophils, COPD assessment test (CAT), 6-minute walking test (6MWT), systolic pulmonary artery pressure (PASP), number of exacerbations in the previous year, lung function test, and serum alpha 1 antitrypsin concentration. A p-value of less than 0.05 was considered statistically significant. Results Out of 28 patients enrolled, 12 (42.9%) were heterozygotes and 16 (57.1%) were MM. Heterozygotes COPD patients, had lower serum alpha 1 antitrypsin concentration compared to MM group (p<0.001). They had higher gastroesophageal reflux disease (GERD)(p= 0.004) and a higher number of exacerbations in the previous year (p=0.016) than MM patients. Lung function variables, smoking habits, inflammatory biomarkers, CAT and 6MWT were not statistically significant. Conclusion COPD patients with a heterozygotes genotype differ from the MM group for serum AAT concentration, presence of GERD and number of exacerbations in the previous year.